Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

2,772 public trials 697 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Active, Not Recruiting

A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)

NCT03385226

Conditions
Cutaneous T Cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +16 more
Locations
  • University Hospital Birmingham Birmingham, United Kingdom
  • Velindre Cancer Centre Cardiff, United Kingdom
  • University Hospital Coventry Coventry, United Kingdom
  • Beatson West of Scotland Cancer Centre Glasgow, United Kingdom
View Trial Details
Active, Not Recruiting

RadiothErapy priMIng for CAR-T

NCT04726787

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • St James's University Hospital Leeds, United Kingdom
  • Kings College Hospital London, United Kingdom
  • Freeman Hospital Newcastle, United Kingdom
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

NCT03671018

Conditions
B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • University of Alabama at Birmingham School of Medicine Birmingham, Alabama, United States
  • City of Hope Duarte, California, United States
  • University of Colorado Hospital - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • University of Miami Miller School of Medicine Miami, Florida, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

NCT04624958

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Guangdong General Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangdong Pharmaceutical University Guangzhou, Guangdong, China
View Trial Details
Active, Not Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

NCT05202782

Conditions
Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Hemic and Lymphatic Diseases, +27 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Active, Not Recruiting

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

NCT02889523

Conditions
DLBCL, Follicular Lymphoma, Hemic and Lymphatic Diseases, +9 more
Locations
  • Institut Jules Bordet Brussels, Belgium
  • CHU de Liege Liège, Belgium
  • CHRU Mont Godinne Yvoir, Belgium
  • Centre Hospitalier Victor Dupouy Argenteuil, France
View all 31 locations
View Trial Details

Related conditions